Previous 10 | Next 10 |
First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an α v β 3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing for antibody drug conjugate (ADC) VIP943 remains on track for mid-2023; expected to be ...
PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced four poster presentations at the upcoming Am...
PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s management team will present...
VIP236 is a first-in-class α V β 3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications Preclinical studies with VIP236 demonstrated promising tumor regression in in vivo cancer models...
In a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents Significant MYC downregulation was observed in patients with double-hit diffuse large B-cell lymphoma (DH-DLBCL) and other B-cel...
Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with Mylotarg™ (gemtuzumab ozogamicin) VIP943 demonstrated ...
Vincerx Pharma press release ( NASDAQ: VINC ): Q3 GAAP EPS of -$0.80 misses by $0.12 . Vincerx Pharma had approximately $66.0 million in cash, cash equivalents and marketable securities as of September 30, 2022, as compared to approximately $111.5 million as of Decembe...
Received Orphan Drug Designation for enitociclib; continue to focus on priority indications IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 expected by year-end IND filings for antibody drug conjugates (ADCs), VIP943 and VIP924, remain on tr...
PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced three poster presentations at the upcom...
Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND filings for antibody drug conjugates (ADCs), VIP943 and VIP924, remain o...
News, Short Squeeze, Breakout and More Instantly...
Vincera Pharma Inc Com Company Name:
VINC Stock Symbol:
NASDAQ Market:
Vincera Pharma Inc Com Website:
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive result...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock,...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warra...